TD Cowen analyst Joseph Thome has maintained their bullish stance on JAZZ stock, giving a Buy rating yesterday.
Joseph Thome has given his Buy rating due to a combination of factors including Jazz Pharmaceuticals’ strong financial performance and promising future prospects. The company reported higher-than-expected revenues in the fourth quarter, driven by robust sales from its oxybate business and Epidiolex. This financial success is further supported by the company’s guidance for 2025, which aligns with market expectations, indicating stable growth.
Additionally, Jazz Pharmaceuticals is making significant strides in its product pipeline, particularly with the anticipated pivotal data for Ziihera in the second half of the year. The management’s confidence in the long-term exclusivity of Epidiolex, despite patent challenges, also contributes to the positive outlook. These elements suggest that the stock is currently undervalued, justifying the Buy rating.
In another report released yesterday, Barclays also maintained a Buy rating on the stock with a $190.00 price target.